{"id":"mrg003","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T18:14:00.401409","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MRG003 functions as a bispecific antibody designed to bridge tumor-associated antigens with immune effector cells, thereby enhancing T-cell activation and anti-tumor responses. By simultaneously targeting both tumor cells and immune cells, the drug aims to overcome immune evasion mechanisms and improve therapeutic efficacy in solid tumors.","oneSentence":"MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:14.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications in phase 3 trials not fully disclosed in public domain)"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT07490119","phase":"PHASE2","title":"Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-06-01","conditions":"RAS Wild Type mCRC","enrollment":31},{"nctId":"NCT07464366","phase":"PHASE2","title":"The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Ji Dongmei","startDate":"2026-03-15","conditions":"Salivary Gland Carcinomas","enrollment":68},{"nctId":"NCT07381699","phase":"PHASE2","title":"MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":30},{"nctId":"NCT05126719","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2023-04-06","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":238},{"nctId":"NCT07394244","phase":"PHASE2","title":"Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-09","conditions":"Cutaneous Squamous Cell Carcinoma (CSCC)","enrollment":38},{"nctId":"NCT06976190","phase":"PHASE3","title":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2025-05-06","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":446},{"nctId":"NCT07331428","phase":"PHASE2","title":"MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-01","conditions":"Nasopharyngeal Carcinoma, Local Recurrence","enrollment":25},{"nctId":"NCT07267338","phase":"PHASE2","title":"Pembrolizumab + MRGOO3 as Neoadjuvant in NPC","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"NPC, Locoregionally Advanced Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT07235566","phase":"PHASE2","title":"MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-21","conditions":"Thyroid Cancer","enrollment":60},{"nctId":"NCT06959108","phase":"PHASE2","title":"Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2025-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":106},{"nctId":"NCT04868162","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-04-23","conditions":"Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","enrollment":116},{"nctId":"NCT07054307","phase":"PHASE1","title":"MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiyan Liu","startDate":"2025-07-30","conditions":"Penile Cancer","enrollment":10},{"nctId":"NCT06530914","phase":"PHASE2","title":"A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Lei Liu","startDate":"2024-08-01","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30},{"nctId":"NCT06509997","phase":"PHASE2","title":"A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Lei Liu","startDate":"2024-08-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05751512","phase":"PHASE3","title":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2023-03","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":180},{"nctId":"NCT05688605","phase":"PHASE1, PHASE2","title":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2022-06-30","conditions":"Advanced Solid Tumors","enrollment":18},{"nctId":"NCT05188209","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-05-24","conditions":"Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma","enrollment":60},{"nctId":"NCT04838964","phase":"PHASE2","title":"A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-04-28","conditions":"Advanced or Metastatic Biliary Tract Cancer","enrollment":80},{"nctId":"NCT04868344","phase":"PHASE1","title":"A Study of MRG003 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Shanghai Miracogen Inc.","startDate":"2018-05-09","conditions":"Advanced Solid Tumors","enrollment":61},{"nctId":"NCT04838548","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2020-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2026 Feb 19","pmid":"41720100","title":"Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial.","journal":"Med (New York, N.Y.)"},{"date":"2024 Jul","pmid":"38820656","title":"A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.","journal":"Cancer treatment reviews"},{"date":"2022 Jul 1","pmid":"35511148","title":"Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.","journal":"JAMA oncology"},{"date":"2022","pmid":"35295841","title":"Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.","journal":"Frontiers in molecular biosciences"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MRG003","genericName":"MRG003","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity. Used for Solid tumors (specific indications in phase 3 trials not fully disclosed in public domain).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}